Pharma China has been predicting a shift by the Chinese general pharmaceutical industry to become increasingly more export-oriented. This Wall Street Journal article confirms our observations by spotlighting the move of Zhejiang Huahai Pharma which received China's first ANDA approval for a Chinese-made finished drug product from the USFDA.

--------------------------------------------------------------------------------------

This is not an article published by Pharma China, and please visit the following website link for the full text of the article.  The availability of the article is under the control of its publisher.  

http://online.wsj.com/article/SB119187230072652477.html?mod=googlenews_wsj

Note: By clicking on the above link, you will leave Pharma China Online. If you wish to return to this website, please click on "Back" button or log onto Pharma China Online again.